18 results on '"F, Durif"'
Search Results
2. Efficacité de la neuromodulation sacrée chez le patient parkinsonien
- Author
-
C. Millet, N. Vedrine, J.-L. Descotes, A. Ruffion, F. Durif, L. Guy, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
- Subjects
Urology ,[SDV]Life Sciences [q-bio] - Abstract
International audience
- Published
- 2022
- Full Text
- View/download PDF
3. A case–control study investigating food addiction in Parkinson patients
- Author
-
Yves Boirie, B. Debilly, F. Durif, Georges Brousse, P.-M. Llorca, A. Marques, Maria Livia Fantini, Philippe Derost, Isabelle Chéreau-Boudet, Ingrid de Chazeron, Céline Lambert, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), TEVA Sante FranceAbbVieAllerganEisai Co LtdGedeon RichterJohnson & JohnsonJohnson & Johnson USAJanssen Biotech IncLundbeck CorporationOtsuka PharmaceuticalRecordattiSanofiTeva, and CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
- Subjects
Male ,medicine.medical_specialty ,Neurology ,Food addiction ,Science ,media_common.quotation_subject ,Impulsivity ,Article ,Night eating syndrome ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Prevalence ,Humans ,Night Eating Syndrome ,Medicine ,Aged ,media_common ,Sex Characteristics ,Multidisciplinary ,business.industry ,Dopaminergic ,Case-control study ,Parkinson Disease ,Middle Aged ,medicine.disease ,030227 psychiatry ,3. Good health ,Eating disorders ,Cross-Sectional Studies ,Risk factors ,Case-Control Studies ,Impulsive Behavior ,Female ,Food Addiction ,medicine.symptom ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,030217 neurology & neurosurgery ,Vigilance (psychology) - Abstract
Eating disorders (EDs) in patients with Parkinson’s disease (PD) are mainly described through impulse control disorders but represent one end of the spectrum of food addiction (FA). Although not formally recognized by DSM-5, FA is well described in the literature on animal models and humans, but data on prevalence and risk factors compared with healthy controls (HCs) are lacking. We conducted a cross-sectional study including 200 patients with PD and 200 age- and gender-matched HCs. Characteristics including clinical data (features of PD/current medication) were collected. FA was rated using DSM-5 criteria and the Questionnaire on Eating and Weight Patterns-Revised (QEWP-R). Patients with PD had more EDs compared to HCs (27.0% vs. 13.0%, respectively, p p = 0.001) and night eating syndrome (7.0% vs. 2.5% p = 0.03). In PD patients, FA was associated with female gender (p = 0.04) and impulsivity (higher attentional non-planning factor) but not with the dose or class of dopaminergic therapy. Vigilance is necessary, especially for PD women and in patients with specific impulsive personality traits. Counterintuitively, agonist dopaminergic treatment should not be used as an indication for screening FA in patients with PD.
- Published
- 2021
- Full Text
- View/download PDF
4. Impact of magnetic fields generated by AC/DC submarine power cables on the behavior of juvenile European lobster (Homarus garnmarus)
- Author
-
Bastien Taormina, Florian Freytet, Rosa H. Escobar-Lux, Carole Di Poi, Nicolas Desroy, Jean-François D’eu, Caroline M. F. Durif, Ann-Lisbeth Agnalt, Antoine Carlier, France Energies Marines [Brest], Dynamiques des Écosystèmes Côtiers (DYNECO), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Laboratoire des Sciences de l'Environnement Marin (LEMAR) (LEMAR), Institut de Recherche pour le Développement (IRD)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Université de Brest (UBO)-Institut Universitaire Européen de la Mer (IUEM), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Institute of Marine Research [Bergen] (IMR), University of Bergen (UiB), Laboratoire Environnement Ressource Bretagne Nord (LERBN), LITTORAL (LITTORAL), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Austevoll Research Station (IMR), University of Bergen (UiB)-University of Bergen (UiB), Dynamiques de l'Environnement Côtier (DYNECO), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), and Institut Français de Recherche pour l'Exploitation de la Mer - Brest (IFREMER Centre de Bretagne)
- Subjects
Health, Toxicology and Mutagenesis ,Anthropogenic impact ,Video Recording ,Context (language use) ,010501 environmental sciences ,Aquatic Science ,Submarine power cable ,01 natural sciences ,orientation ,03 medical and health sciences ,Homing Behavior ,Homarus gammarus ,Avoidance Learning ,Animals ,Juvenile ,cancer ,crab ,14. Life underwater ,atlantic spiny lobster ,electromagnetic-fields ,navigation ,Ships ,030304 developmental biology ,0105 earth and related environmental sciences ,0303 health sciences ,Behavior ,Behavior, Animal ,biology ,ACL ,potential impacts ,Submarine ,Marine invertebrates ,Models, Theoretical ,biology.organism_classification ,mortality ,Life stage ,Nephropidae ,Magnetic field ,Europe ,Magnetic Fields ,Oceanography ,exposure ,Exploratory Behavior ,Environmental science ,[SDE.BE]Environmental Sciences/Biodiversity and Ecology - Abstract
WOS:000517853700004; The number of submarine power cables using either direct or alternating current is expected to increase drastically in coming decades. Data concerning the impact of magnetic fields generated by these cables on marine invertebrates are scarce. In this context, the aim of this study was to explore the potential impact of anthropogenic static and time-varying magnetic fields on the behavior of recently settled juvenile European lobsters (Homarus gammarus) using two different behavioral assays. Day-light conditions were used to stimulate the sheltering behavior and facilitate the video tracking. We showed that juvenile lobsters did not exhibit any change of behavior when submitted to an artificial magnetic field gradient (maximum intensity of 200 mu T) compared to non-exposed lobsters in the ambient magnetic field. Additionally, no influence was noted on either the lobsters' ability to find shelter or modified their exploratory behavior after one week of exposure to anthropogenic magnetic fields (225 +/- 5 mu T) which remained similar to those observed in control individuals. It appears that static and time-varying anthropogenic magnetic fields, at these intensities, do not significantly impact the behavior of juvenile European lobsters in daylight conditions. Nevertheless, to form a complete picture for this biological model, further studies are needed on the other life stages as they may respond differently.
- Published
- 2020
- Full Text
- View/download PDF
5. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study
- Author
-
Vanessa Brochard, Fanny Artaud, Frédéric Bourdain, S. Sambin, Valérie Mesnage, O. Rascol, Clemens R. Scherzer, Fabienne Ory-Magne, Isabelle Rieu, Jean-Christophe Corvol, Fanny Pineau, Merry Mazmanian, Louise-Laure Mariani, Monica Roy, Hélène Bertrand, Marie Vidailhet, Graziella Mangone, Tiphaine Vidal, Benjamin Le Toullec, Bérangère Debilly, Sara Leder, Emmanuel Roze, Bertrand Degos, Samir Bekadar, Cecilia Bonnet, Genetic core: Alexis Brice, Jean-Philippe Brandel, Antoine Faurie-Grepon, Hana You, Monique Galitsky, Stephan Klebe, Julia Kraemmer, J. Ihle, Mostafa Hajji, Virginie Bayet, David Grabli, Richard Levy, P. Derkinderen, Hakima Manseur, Ll Mariani, Julie Socha, Suzanne Lesage, Florence Cormier-Dequaire, Statistical analyses, A. Marques, Fernando Pico, Khadija Tahiri, Andreas Hartmann, Stéphane Bernard, Olivier Rascol, Eve Benchetrit, Alexis Brice, Julia Muellner, F. Durif, Violaine Plante-Bordeneuve, Sponsor activities, J-C Corvol, Alain Mallet, Co-investigators, Coralie Villeret, Pascal Derkinderen, Franck Durif, Anne-Marie Bonnet, Neuropsychologists, Christine Brefel-Courbon, Mélissa Tir, A. Elbaz, Lucette Lacomblez, Alexis Elbaz, Elsa Pomies, F. Artaud, Principal investigators for sites, Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), NS-Park/FCRIN Network, UMS 015, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Sud - Paris 11 - Faculté de médecine (UP11 UFR Médecine), Université Paris-Sud - Paris 11 (UP11), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Foch [Suresnes], Fondation A. Rothschild, Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Clermont-Ferrand, CHU Saint-Antoine [AP-HP], Centre Hospitalier de Versailles André Mignot (CHV), Hôpital Henri Mondor, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ANR-10-IAIHU-06 Ministère des Affaires Sociales et de la Santé: AOR0810 Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM: ANSM-2013, This project was funded by grants from the French Ministry of Health (Programme Hospitalier de Recherche Clinique, AOR0810 ) and from the French Drug Agency (Agence Nationale de Sécurité et des Médicaments, ANSM-2013 ). The research leading to these results has received funding from the program ' Investissements d’Avenir ' ANR-10-IAIHU-06 . We want to express our gratitude to all the participants who made this study possible., ANR-10-IAHU-0006,IHU-A-ICM,Institut de Neurosciences Translationnelles de Paris(2010), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Longitudinal study ,Multifactorial Inheritance ,Parkinson's disease ,Movement disorders ,Genome-wide association study ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Genetic predisposition ,Humans ,Longitudinal Studies ,Age of Onset ,Adverse effect ,Generalized estimating equation ,Aged ,business.industry ,Parkinson Disease ,Middle Aged ,medicine.disease ,3. Good health ,Disruptive, Impulse Control, and Conduct Disorders ,030104 developmental biology ,Neurology ,Female ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Neurology (clinical) ,France ,Geriatrics and Gerontology ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
International audience; Objective: To examine the relationship between a Parkinson's disease (PD) polygenic risk score (PRS) and impulse control disorders (ICDs) in PD. Background: Genome wide association studies (GWAS) have brought forth a PRS associated with increased risk of PD and younger disease onset. ICDs are frequent adverse effects of dopaminergic drugs and are also more frequent in patients with younger disease onset. It is unknown whether ICDs and PD share genetic susceptibility. Methods: We used data from a multicenter longitudinal cohort of PD patients with annual visits up to 6 years (DIG-PD). At each visit ICDs, defined as compulsive gambling, buying, eating, or sexual behavior were evaluated by movement disorders specialists. We genotyped DNAs using the Megachip assay (Illumina) and calculated a weighted PRS based on 90 SNPs associated with PD. We estimated the association between PRS and prevalence of ICDs at each visit using Poisson generalized estimating equations, adjusted for dopaminergic treatment and other known risk factors for ICDs. Results: Of 403 patients, 185 developed ICDs. Patients with younger age at onset had a higher prevalence of ICDs (p < 0.001) as well as higher PRS values (p = 0.06). At baseline, there was no association between the PRS and ICDs (overall, p = 0.84). The prevalence of ICDs increased over time similarly across the quartiles of the PRS (overall, p = 0.88; DA users, p = 0.99). Conclusion: Despite younger disease onset being associated with both higher PRS and ICD prevalence, our findings are not in favor of common susceptibility genes for PD and ICDs.
- Published
- 2020
- Full Text
- View/download PDF
6. Freshwater eels: A symbol of the effects of global change
- Author
-
Maria Mateo, Hilaire Drouineau, Martin Castonguay, Caroline M. F. Durif, Eric Rochard, Guy Verreault, Patrick Lambert, Kazuki Yokouchi, Ecosystèmes aquatiques et changements globaux (UR EABX), and Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)
- Subjects
0106 biological sciences ,Anguilla rostrata ,endocrine system ,animal structures ,Context (language use) ,Management, Monitoring, Policy and Law ,Aquatic Science ,Biology ,Oceanography ,010603 evolutionary biology ,01 natural sciences ,Anguillidae ,ANGUILLA ROSTRATA ,14. Life underwater ,Japanese eel ,Ecology, Evolution, Behavior and Systematics ,SALMO SALAR ,010604 marine biology & hydrobiology ,fungi ,Cumulative effects ,ANGUILLA ANGUILLA ,ANGUILLIDAE ,biology.organism_classification ,Fishery ,Overexploitation ,Habitat destruction ,Habitat ,ANGUILLA JAPONICA ,[SDV.EE.BIO]Life Sciences [q-bio]/Ecology, environment/Bioclimatology ,[SDE.BE]Environmental Sciences/Biodiversity and Ecology - Abstract
International audience; Temperate eels Anguilla anguilla (European eel), A. rostrata (American eel) and A. japonica (Japanese eel) are three catadromous species which have been declining since the 1970s/1980s despite their remarkable adaptive capacity. Because of their specific life cycles, which share distant oceanic spawning grounds and continental growth stage, eels are affected by five components of the global change: (a) climate change affecting larval survival and drift, (b) an increase in pollution leading to high levels of contamination exacerbated by their high lipid levels, (c) increasing fragmentation and habitat loss that reduce dramatically the amount of available habitats and induce increased spawner mortality, (d) the appearance of Anguillicola crassus a parasitic alien nematode that impairs spawning success, and (e) the impact of commercial and recreational fisheries for all life stages of eel. In this context, the rapid increases of pressures during the "Great Acceleration" have surpassed the adaptive capacity of eels. This illustrates that cumulative effects of global change can lead to the collapse of species, even in species that have amazingly high adaptive capacities.
- Published
- 2018
- Full Text
- View/download PDF
7. Hallucinations in schizophrenia and Parkinson's disease: an analysis of ă sensory modalities involved and the repercussion on patients
- Author
-
Ana Marques, Miguel Ulla, A.M. Tronche, I. de Chazeron, C. Lançon, G. Fénelon, Georges Brousse, Philippe Derost, Bruno Pereira, David Misdrahi, Isabelle Chéreau-Boudet, Renaud Jardri, Pierre-Michel Llorca, F. Durif, Raymund Schwan, B. Debilly, University Institute for Intelligent Systems and Numerical Applications in Engineering, University of Las Palmas de Gran Canaria (ULPGC), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre d'Ingéniérie Hydraulique, EDF (EDF), Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), Service de Neurologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Service de neurologie, Hôpital Gabriel Montpied, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Universitaire de France, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Fondation FondaMental [Créteil], Université de Lille, CNRS, CHU Lille, Université d'Auvergne - Clermont-Ferrand I [UdA], Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab], Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA], Centre hospitalier Charles Perrens [Bordeaux], École normale supérieure - Paris [ENS-PSL], Institut Mondor de Recherche Biomédicale [IMRB], Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy], Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ], Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants [SPMC], and Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux [NPsy-Sydo]
- Subjects
Adult ,Disease specific ,medicine.medical_specialty ,Parkinson's disease ,Hallucinations ,[SHS.PSY]Humanities and Social Sciences/Psychology ,Disease ,Audiology ,behavioral disciplines and activities ,Article ,[SHS]Humanities and Social Sciences ,03 medical and health sciences ,[SCCO]Cognitive science ,0302 clinical medicine ,Stimulus modality ,mental disorders ,medicine ,Humans ,Psychiatry ,ComputingMilieux_MISCELLANEOUS ,Aged ,Multidisciplinary ,Modalities ,business.industry ,Parkinson Disease ,Middle Aged ,Guardian angel ,medicine.disease ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,Visual Hallucination ,030227 psychiatry ,Hallucinating ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,Schizophrenia ,Quality of Life ,business ,030217 neurology & neurosurgery - Abstract
Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the more frequent. In Parkinson’s disease, the descriptions of hallucination modalities are sparse, but the hallucinations do tend to have less negative consequences. Our study aims to explore the phenomenology of hallucinations in both hallucinating schizophrenia patients and Parkinson’s disease patients using the Psycho-Sensory hAllucinations Scale (PSAS). The main objective is to describe the phenomena of these clinical symptoms in those two specific populations. Each hallucinatory sensory modality significantly differed between Parkinson’s disease and schizophrenia patients. Auditory, olfactory/gustatory and cœnesthetic hallucinations were more frequent in schizophrenia than visual hallucinations. The guardian angel item, usually not explored in schizophrenia, was described by 46% of these patients. The combination of auditory and visual hallucinations was the most frequent for both Parkinson’s disease and schizophrenia. The repercussion index summing characteristics of each hallucination (frequency, duration, negative aspects, conviction, impact, control and sound intensity) was always higher for schizophrenia. A broader view including widespread characteristics and interdisciplinary works must be encouraged to better understand the complexity of the process involved in hallucinations.
- Published
- 2016
- Full Text
- View/download PDF
8. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease
- Author
-
Pierre Jean Saulnier, Régis Bordet, Jean Christophe Devedjian, Caroline Giordana, F. Durif, Thomas Bardyn, Francis Vasseur, Caroline Moreau, Olivier Rascol, Sayah Meguig, Gregory Petyt, Marie Vidailhet, Mirela Faighel, François Tison, Jean-Luc Houeto, Christine Tranchant, Alain Duhamel, Alain Destée, Christine Brefel-Courbon, Sophie Drapier, Alexandre Eusebio, Jean-Philippe Azulay, Arnaud Delval, Julien Labreuche, David Maltête, Nathalie Rouaix, Fabienne Ory-Magne, Luc Defebvre, Ouhaid Lagha-Boukbiza, David Devos, Kathy Dujardin, Bettina Debû, Bernard Sablonnière, Valérie Fraix, Jean-Christophe Corvol, Dominique Guehl, Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Imagerie cérébrale et handicaps neurologiques (ICHN), Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), INSERM U836, équipe 11, Fonctions cérébrales et neuromodulation, Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service de Neurologie, CHU Grenoble-CHU Grenoble, Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire de neurosciences expérimentales et cliniques (LNEC), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Neurology, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Santé publique : épidémiologie et qualité des soins-EA 2694 (CERIM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Imagerie cérébrale et handicaps neurologiques, CIC Toulouse, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service de Neurologie, CHU Grenoble, Micro et Nanomédecines Biomimétiques, Université d'Auvergne - Clermont-Ferrand I (UdA)-CHU Clermont-Ferrand, Institut des Neurosciences Cliniques de Rennes (INCR)-CHU Pontchaillou [Rennes]-Université européenne de Bretagne - European University of Brittany (UEB)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC CHU (toulouse)/inserm, Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Fonctionnelles et Pathologies, Hôpital Roger Salengro-PRES Université Lille Nord de France-EA 4559/1046-Université de Lille, Droit et Santé, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes = Institute of Clinical Neurosciences of Rennes (INCR), Département de neurologie [Lille], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP]
- Subjects
Levodopa ,Parkinson's disease ,Genotype ,Dopamine ,[SDV]Life Sciences [q-bio] ,methylphenidate ,Pharmacology ,Catechol O-Methyltransferase ,Bioinformatics ,Double-Blind Method ,medicine ,Humans ,Genetic Predisposition to Disease ,levodopa ,Aged ,Dopamine transporter ,pharmacogenetics ,Dopamine Plasma Membrane Transport Proteins ,Polymorphism, Genetic ,Catechol-O-methyl transferase ,biology ,Methylphenidate ,Parkinson Disease ,Original Articles ,Middle Aged ,medicine.disease ,nervous system diseases ,3. Good health ,biology.protein ,Parkinson’s disease ,cognitive disorders ,Neurology (clinical) ,Monoamine oxidase B ,Psychology ,medicine.drug ,rs4680 - Abstract
International audience; After more than 50 years of treating Parkinson’s disease with l-DOPA, there are still no guidelines on setting the optimal dose for a given patient. The dopamine transporter type 1, now known as solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) is the most powerful determinant of dopamine neurotransmission and might therefore influence the treatment response. We recently demonstrated that methylphenidate (a dopamine transporter inhibitor) is effective in patients with Parkinson’s disease with motor and gait disorders. The objective of the present study was to determine whether genetic variants of the dopamine transporter type 1-encoding gene (SLC6A3) are associated with differences in the response to treatment of motor symptoms and gait disorders with l-DOPA and methylphenidate (with respect to the demographic, the disease and the treatment parameters and the other genes involved in the dopaminergic neurotransmission). This analysis was part of a multicentre, parallel-group, double-blind, placebo-controlled, randomized clinical trial of methylphenidate in Parkinson’s disease (Protocol ID:2008-005801-20; ClinicalTrials.gov:NCT00914095). We scored the motor Unified Parkinson's Disease Rating Scale and the Stand-Walk-Sit Test before and after a standardized acute l-DOPA challenge before randomization and then after 3 months of methylphenidate treatment. Patients were screened for variants of genes involved in dopamine metabolism: rs28363170 and rs3836790 polymorphisms in the SLC6A3 gene, rs921451 and rs3837091 in the DDC gene (encoding the aromatic L-amino acid decarboxylase involved in the synthesis of dopamine from l-DOPA), rs1799836 in the MAOB gene (coding for monoamine oxidase B) and rs4680 in the COMT gene (coding for catechol-O-methyltransferase). Investigators and patients were blinded to the genotyping data throughout the study. Eighty-one subjects were genotyped and 61 were analysed for their acute motor response to l-DOPA. The SLC6A3 variants were significantly associated with greater efficacy of l-DOPA for motor symptoms. The SLC6A3 variants were also associated with greater efficacy of methylphenidate for motor symptoms and gait disorders in the ON l-DOPA condition. The difference between motor Unified Parkinson's Disease Rating Scale scores for patients with different SLC6A3 genotypes was statistically significant in a multivariate analysis that took account of other disease-related, treatment-related and pharmacogenetic parameters. Our preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson’s disease. Further studies are required to assess the possible value of these genotypes for (i) guiding l-DOPA dose adaptations over the long term; and (ii) establishing the risk/benefit balance associated with methylphenidate treatment for gait disorders.
- Published
- 2015
- Full Text
- View/download PDF
9. Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease
- Author
-
F. Durif, Raymund Schwan, Isabelle Chéreau-Boudet, Bruno Pereira, Ana Marques, G. Fénelon, Georges Brousse, I. de Chazeron, B. Debilly, Pierre-Michel Llorca, A.M. Tronche, Christophe Lançon, David Misdrahi, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand, Université d'Auvergne - Clermont-Ferrand I (UdA), Fondation FondaMental [Créteil], Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), and École normale supérieure - Paris (ENS Paris)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Parkinson's disease ,Psychometrics ,Hallucinations ,Scales ,Disease ,Statistics, Nonparametric ,Stimulus modality ,Internal consistency ,medicine ,Humans ,Psychiatry ,Biological Psychiatry ,Aged ,Psychiatric Status Rating Scales ,Modalities ,Sensory Hallucinations ,Reproducibility of Results ,Parkinson Disease ,Guardian angel ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Convergent validity ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,Schizophrenia ,Female ,Psychology ,Clinical psychology - Abstract
International audience; Objective: If hallucinations are the most common of schizophrenic symptoms, they have been described in other pathologies such as Parkinson's disease (PD) but may differ considerably in their phenomenology. However, no multi-modal clinical scale with a transnosographic approach has been developed today. The purpose of this study was to create and validate a new tool for the hetero-assessment of all sensory modalities of hallucinations schizo-phrenia (SCZ) and in PD.Method: Scale items were generated by literature review and validated by medical board. A study was then made to evaluate psychometric properties of the Psycho-Sensory hAllucinations Scale (PSAS) that include four domains (auditory, visual, olfactory and gustatory, cenesthetic modalities) and one specific item 'guardian angel'.Results: It was then validated in 137 patients: 86 PD (53.5% male; mean age = 53.3 years) and 51 SCZ (64.7% male; mean age = 38.5 years). Factorial analysis of the PSAS found four factors. The PSAS showed good internal consistency [Kuder-Richardson alpha coefficient 0.49 to 0.77] and good test-retest reliability [Agreement % = 0.75 to 0.97] and inter-rater reliability [Agreement % = 0.78 to 1.0]. The convergent validity illustrates the concomitant evaluation of the concept between PSAS and PANSS P3 and UPDRS1 I2.Conclusion: The PSAS can be useful to describe the whole hallucination and its evolution during the course of the disease and treatment in schizophrenia and PD. Moreover, it can allow us to undertake a clinic-pathological comparison of hallucination modalities between these two diseases, to enhance our understanding of their precise neurological mechanisms.
- Published
- 2015
- Full Text
- View/download PDF
10. Les investisseurs particuliers et l’ISR ; une relation complexe
- Author
-
I. Prim Allaz, F. Durif, H. Sami, Prim-Allaz, Isabelle, ESG-UQAM, Université du Québec à Montréal = University of Québec in Montréal (UQAM), COACTIS (COACTIS), and Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM)
- Subjects
Economics and Econometrics ,Strategy and Management ,05 social sciences ,Investissement socialement responsable ,12. Responsible consumption ,[SHS]Humanities and Social Sciences ,0502 economics and business ,investissuers particuliers ,[SHS.GESTION]Humanities and Social Sciences/Business administration ,050211 marketing ,[SHS] Humanities and Social Sciences ,Business and International Management ,ISR ,[SHS.GESTION] Humanities and Social Sciences/Business administration ,050203 business & management - Abstract
While Socially Responsible Investing (“SRI”) receives significant attention among institutional investors, the weight of individual investors remains weak. Few studies have attempted to understand this phenomenon. This paper aims to fill this gap in the literature by analyzing the SRI funds market and its inefficiency and by suggesting possible solutions. An analysis of SRI individual investors’ behaviours based on a survey of a representative panel of 1050 Ontario consumers is thus proposed. The paper proceeds to study the motivations of individual investors as well as their decision criteria for the selection of SRI funds., Si l’investissement socialement responsable (ISR) séduit de plus en plus d’investisseurs institutionnels, le développement du marché des particuliers reste timide. Peu d’études ont essayé de comprendre ce phénomène. Via une enquête menée auprès d’un panel de consommateurs représentatifs de la province de l’Ontario, cet article présente une lecture des comportements des investisseurs particuliers face à l’ISR. Les critères de décisions quant à la sélection de fonds d’ISR et les profils des particuliers en possédant sont exposés.
- Published
- 2013
11. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
- Author
-
Caroline Giordana, Jean-Philippe Azulay, Alain Duhamel, Jean-Christophe Corvol, Christine Tranchant, Alexandre Eusebio, David Maltête, Olivier Rascol, Mirela Faighel, F. Durif, Kathy Dujardin, Marie Vidailhet, Alain Destée, Jean-Luc Houeto, Valérie Fraix, François Tison, Gregory Petyt, Isabelle Vuillaume, Sophie Drapier, Christine Brefel-Courbon, Pierre-Jean Saulnier, Ouhaid Lagha-Boukbiza, David Devos, Dominique Guehl, Luc Defebvre, Fabienne Ory-Magne, Bettina Debû, Caroline Moreau, Bernard Sablonnière, Arnaud Delval, Régis Bordet, Bastiaan R. Bloem, Département de neurologie [Lille], Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Centre de Biologie-Pathologie, UF de Neurobiologie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Imagerie cérébrale et handicaps neurologiques (ICHN), Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de la Timone [CHU - APHM] (TIMONE), INSERM U836, équipe 11, Fonctions cérébrales et neuromodulation, Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service de Neurologie, CHU Grenoble-CHU Grenoble, Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire de neurosciences expérimentales et cliniques (LNEC), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Department of Clinical Genetics, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neurology, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Santé publique : épidémiologie et qualité des soins-EA 2694 (CERIM), Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Imagerie cérébrale et handicaps neurologiques, CIC Toulouse, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service de Neurologie, CHU Grenoble, Micro et Nanomédecines Biomimétiques, Université Bretagne Loire (UBL)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université d'Angers (UA), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC CHU (toulouse)/inserm, Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Fonctionnelles et Pathologies, Hôpital Roger Salengro-PRES Université Lille Nord de France-EA 4559/1046-Université de Lille, Droit et Santé, Pollak, Pierre, and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP]
- Subjects
Male ,Movement disorders ,Parkinson's disease ,Deep Brain Stimulation ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Placebo-controlled study ,Hypokinesia ,law.invention ,0302 clinical medicine ,Dopamine Uptake Inhibitors ,Randomized controlled trial ,law ,0303 health sciences ,Methylphenidate ,Parkinson Disease ,Middle Aged ,3. Good health ,Treatment Outcome ,Human Movement & Fatigue [DCN MP - Plasticity and memory NCEBP 10] ,Anesthesia ,Female ,France ,medicine.symptom ,medicine.drug ,medicine.medical_specialty ,Deep brain stimulation ,Methylphenidate/therapeutic use ,Placebo ,Dopamine Uptake Inhibitors/therapeutic use ,03 medical and health sciences ,Double-Blind Method ,Gait Disorders, Neurologic/etiology/therapy ,medicine ,Humans ,Gait Disorders, Neurologic ,Aged ,030304 developmental biology ,business.industry ,Parkinson Disease/complications/therapy ,medicine.disease ,ddc:616.8 ,Physical therapy ,Hypokinesia/etiology/therapy ,Neurology (clinical) ,business ,human activities ,030217 neurology & neurosurgery - Abstract
Item does not contain fulltext BACKGROUND: Despite optimum medical management, many patients with Parkinson's disease are incapacitated by gait disorders including freezing of gait. We aimed to assess whether methylphenidate--through its combined action on dopamine and noradrenaline reuptake--would improve gait disorders and freezing of gate in patients with advanced Parkinson's disease without dementia who also received subthalamic nucleus stimulation. METHODS: This multicentre, parallel, double-blind, placebo-controlled, randomised trial was done in 13 movement disorders departments in France between October, 2009, and December, 2011. Eligible patients were younger than 80 years and had Parkinson's disease, severe gait disorders, and freezing of gate despite optimised treatment of motor fluctuations with dopaminergic drugs and subthalamic stimulation. We randomly assigned patients (1:1 with a computer random-number generator in blocks of four) to receive methylphenidate (1 mg/kg per day) or placebo capsules for 90 days. Patients, their carers, study staff, investigators, and data analysts were masked to treatment allocation. To control for confounding effects of levodopa we assessed patients under standardised conditions with an acute levodopa challenge. Our primary outcome was a change in the number of steps during the stand-walk-sit (SWS) test without levodopa. We compared the respective mean numbers of steps at day 90 in the methylphenidate and placebo groups in a covariance analysis and adjusted for baseline differences. This trial is registered with ClinicalTrials.gov, number NCT00914095. FINDINGS: We screened 81 patients and randomly assigned 35 to receive methylphenidate and 34 to receive placebo. 33 patients in the methylphenidate group and 32 patients in the placebo group completed the study. Efficacy outcomes were assessed in the patients who completed the study. Compared with patients in the placebo group (median 33 steps [IQR 26-45]), the patients in the methylphenidate group made fewer steps at 90 days (31 [26-42], F((1, 62))=6.1, p=0.017, adjusted size effect 0.61). Adverse events were analysed in all randomly assigned patients. There were significantly more adverse events in the methylphenidate group compared with placebo. Patients on methylphenidate had a significant increase in heart rate (mean 3.6 [SD 7.2] beats per min) and decrease in weight (mean 2.2 [SD 1.8] kg) compared with the placebo group. INTERPRETATION: Methylphenidate improved gait hypokinesia and freezing in patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation. Methylphenidate represents a therapeutic option in the treatment of gait disorders at the advanced stage of Parkinson's disease. The long term risk-benefit balance should be further studied. FUNDING: French Ministry of Health and Novartis Pharma. 01 juli 2012
- Published
- 2012
- Full Text
- View/download PDF
12. La maladie de Parkinson idiopathique : une maladie métabolique ?
- Author
-
Isabelle Rieu, S. Bannier, Miguel Ulla, A. Marques, Béatrice Morio, Philippe Derost, B. Debilly, F. Durif, Yves Boirie, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Nutrition Humaine (UNH), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Institut National de la Recherche Agronomique (INRA), UFR de Médecine, Département de Neurologie, CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Clermont Université-Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Recherche Agronomique (INRA), Centre Hospitalier Universitaire de Clermont-Ferrand, and Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université
- Subjects
INCREASED ENERGY-EXPENDITURE ,medicine.medical_specialty ,FOOD-INTAKE ,Deep brain stimulation ,Parkinson's disease ,medicine.medical_treatment ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,Disease ,BODY-WEIGHT GAIN ,Central nervous system disease ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Degenerative disease ,MASS INDEX ,Diabetes mellitus ,medicine ,ELDERLY-PATIENTS ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,RISK ,0303 health sciences ,Autonomous nervous system ,[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior ,business.industry ,[SCCO.NEUR]Cognitive science/Neuroscience ,Energetic metabolism ,ACTIVATED PROTEIN-KINASE ,Dysautonomia ,Body weight gain ,[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences ,medicine.disease ,SUBTHALAMIC NUCLEUS STIMULATION ,3. Good health ,Surgery ,Subthalamic nucleus ,Neurology ,Neurology (clinical) ,medicine.symptom ,business ,FOLLOW-UP ,030217 neurology & neurosurgery ,DEEP BRAIN-STIMULATION - Abstract
International audience; Parkinson's disease is a neurodegenerative disorder clinically characterized by motor impairments (tremor, bradykinesia, rigidity and postural instability) associated or not with non-motor complications (cognitive disorders, dysautonomia) Most of patients loose weight during evolution of their disease Dysregulations of hypothalamus, which is considered as the regulatory center of satiety and energy metabolism, could play a major role in this phenomenon Deep brain stimulation of the subthalamic nucleus (NST) is an effective method to treat patients with advanced Parkinson's disease providing marked improvement of motor impairments. This chirurgical procedure also induces a rapid and strong body weight gain and sometimes obesity. This post-operative weight gain, which exceeds largely weight lost recorded in non-operated patient, could be responsible of metabolic disorders (such as diabetes) and cardiovascular diseases. This review describes body weight variations generated by Parkinson' disease and deep brain stimulation of the NST, and focuses on metabolic disorders capable to explain them: Finally, this review emphasizes on the importance of an adequate nutritional follow up care for parkinsonian patient (C) 2010 Elsevier Masson SAS All rights reserved
- Published
- 2010
- Full Text
- View/download PDF
13. Assessment of metabolic changes in the striatum of a rat model of parkinsonism: an in vivo (1)H MRS study
- Author
-
N, Kickler, E, Lacombe, C, Chassain, F, Durif, A, Krainik, R, Farion, P, Provent, C, Segebarth, C, Rémy, M, Savasta, INSERM U836, équipe 5, Neuro-imagerie fonctionnelle et métabolique, Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), INSERM U836, équipe 10, Dynamique des réseaux neuronaux du mouvement, and Dojat, Michel
- Subjects
Male ,Magnetic Resonance Spectroscopy ,MESH: Humans ,MESH: Rats ,MESH: Magnetic Resonance Spectroscopy ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,Parkinson Disease ,MESH: Rats, Sprague-Dawley ,Corpus Striatum ,MESH: Male ,Rats ,MESH: Corpus Striatum ,Rats, Sprague-Dawley ,Disease Models, Animal ,nervous system ,Animals ,Humans ,MESH: Animals ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,MESH: Protons ,Protons ,MESH: Disease Models, Animal ,MESH: Parkinson Disease - Abstract
Degeneration of the dopaminergic neurons of the substantia nigra pars compacta in Parkinson's disease induces an abnormal activation of the glutamatergic neurotransmission system within the basal ganglia network and related structures. The aim of this study was to use proton MRS to show metabolic changes in the striatum of 6-hydroxydopamine-lesioned rats, a rodent animal model of Parkinson's disease. Animals were examined before and after extensive lesioning of the nigral dopaminergic neurons and after acute administration of L-3,4-dihydroxyphenylalanine. No significant alterations in glutamate concentrations, assessed by the MR signal dominated by glutamate with minor contributions from glutamine and γ-aminobutyric acid, could be measured. The total choline/total creatine ratio was found to be reduced in the striatum of the ipsilateral hemisphere. Copyright © 2008 John Wiley & Sons, Ltd.
- Published
- 2009
- Full Text
- View/download PDF
14. Relationship between locomotor activity, environmental factors, and timing of the spawning migration in the European eel, Anguilla anguilla
- Author
-
Pierre Elie, Jacques Rives, Claude Gosset, Francois Travade, Caroline M. F. Durif, INSTITUT OF MARINE RESEARCH OSLO NOR, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Ecosystèmes estuariens et poissons migrateurs amphihalins (UR EPBX), Centre national du machinisme agricole, du génie rural, des eaux et forêts (CEMAGREF), EDF (EDF), Ecologie Comportementale et Biologie des Populations de Poissons (ECOBIOP), and Institut National de la Recherche Agronomique (INRA)-Université de Pau et des Pays de l'Adour (UPPA)
- Subjects
0106 biological sciences ,endocrine system ,animal structures ,Zoology ,Aquatic Science ,medicine.disease_cause ,migration ,010603 evolutionary biology ,01 natural sciences ,ATLANTIQUE OCEAN ,LOCOMOTOR ACTIVITY ,DOWNSTREAM MIGRATION ,ENVIRONMENTAL FACTOR ,PREDICTION ,ANGUILLA ANGUILLA ,ATLANTIC OCEAN ,FACTEUR ENVIRONNEMENTAL ,Tap water ,poisson ,Anguillidae ,anguille ,Sciences et techniques des pêches ,medicine ,Sexual maturity ,14. Life underwater ,Turbidity ,Sciences and technics of fishery ,geography ,geography.geographical_feature_category ,biology ,Chemistry ,010604 marine biology & hydrobiology ,Environmental factor ,Silvering ,Estuary ,anguilla ,biology.organism_classification ,6. Clean water ,Fishery ,activité motrice ,migration d'avalaison ,[SDE]Environmental Sciences ,Stage (hydrology) - Abstract
International audience; At the onset of sexual maturation, European eels Anguilla anguilla exhibit high locomotor activity which may correspond to migratory restlessness. We measured activity of captive eels and determined whether it correlated with downstream runs of silver eels as well as changes in environmental factors. Groups of eels at different stages of the silvering process (yellow to silver stage) were tagged and placed in separate tanks supplied with either river or tap water. Activity was measured by means of a flat-board antenna placed vertically in the middle of the tank at the surface of the water.Wild migrating silver eels were caught in the nearby river. Activity of eels in the river water tanks increased 1 to 2 days before downstream migrating eels were caught in the trap, and concurrently with a rise in turbidity and a decrease in conductivity. Activity of eels in the tap water tank showed a different pattern, which did not correspond to downstream runs. A peak in activity corresponded to a drop in tap water pH. It is concluded that eels do show periods of high locomotor activity at the onset of migration and this could be used to predict downstream migration. Movements are triggered by changes in water composition (as opposed to changes in discharge, atmospheric pressure and lunar cycle) measured using turbidity and/or conductivity as proxies. If eels are able to detect such small changes in water conductivity (80 μS cm−1), they may use it to find their way to the estuary.; Au tout début de leur maturation sexuelle, les anguilles européennes, Anguilla anguilla, présentent une forte agitation qui pourrait correspondre aux premiers mouvements migratoires. L'objectif de cette étude est de déterminer si ces périodes d'activité correspondent aux pics de dévalaison d'anguilles argentées en rivière et si elles peuvent être associées aux variations de certains facteurs environnementaux. Plusieurs lots d'anguilles (stades jaune et argenté) ont été marqués et placés dans des bassins séparés, alimentés soit en eau de la rivière, soit en eau de ville. L'activité des anguilles est mesurée par l'intermédiaire d'une antenne de détection située verticalement au milieu du bassin, près de la surface. Un piège de dévalaison permet de capturer les anguilles en migration dans la rivière. L'activité des anguilles en bassins alimentés par la rivière ont une activité accrue 1 à 2 jours avant la capture d'anguilles de dévalaison dans le piège et ces périodes correspondent à une augmentation de la turbidité et à une diminution de la conductivité. Les individus dans le bassin eau de ville présentent un comportement différent et l'unique pic d'activité correspond à une baisse du pH. En conclusion, les anguilles montrent bien des périodes d'activité intense au moment de la dévalaison et ceci pourrait être utilisé pour prévoir les pics de dévalaison. Les mouvements sont déclenchés par des variations dans la composition de l'eau de la rivière (par opposition à des variations de débit, de pression atmosphérique et au cycle lunaire) visibles à travers les changements de turbidité et/ou de conductivité. Si les anguilles sont capables de percevoir des variations aussi faibles de conductivité (80 μS cm−1), ceci pourrait constituer un signal pour l'orientation vers l'aval.
- Published
- 2008
- Full Text
- View/download PDF
15. Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes
- Author
-
Alexis Brice, A. Lagueny, Lucie Guyant-Maréchal, Laurent Vercueil, C.P. Jedynak, G. Ponsot, Emmanuel Roze, Christine Tranchant, M.A. Cournelle, Didier Hannequin, F. Durif, Philippe Damier, Stéphane Thobois, S. Tezenas du Montcel, Bernard Echenne, J. L. Houeto, Fabienne Clot, Alexandra Durr, M. Vidailhet, Diane Doummar, Agnès Camuzat, Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neurologie et thérapeutique expérimentale, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de neurologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Neurobiologie des processus adaptatifs (NPA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Clinique neurologique, Hôpital Laennec, Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Service de Neurologie, Hôpital du Haut-L'Evêque, Service de Clinique Neurologique, CHU Grenoble, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Génétique médicale et fonctionnelle du cancer et des maladies neuropsychiatriques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de La Milétrie, Service de neuropédiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Saint-Vincent de Paul, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Pédiatrie, Centre Hospitalier du Pays d'Aix, Service de Neurologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Service de Neuropédiatrie, Hôpital Gui de Chauliac [Montpellier], Département de Neurologie, CHU Strasbourg-Hopital Civil, This work was supported by INSERM, Réseau National Dystonies and GIS-Maladies Rares, and the patients' associations AMADYS and Ligue Française Contre la Dystonie., Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], Hôpital Gui de Chauliac [CHU Montpellier], and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
Male ,Myoclonus ,DNA Mutational Analysis ,Cohort Studies ,0302 clinical medicine ,myoclonus dystonia ,Missense mutation ,Child ,Genetics (clinical) ,Dystonia ,Genetics ,0303 health sciences ,[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences ,Myoclonic dystonia ,Syndrome ,Middle Aged ,Penetrance ,3. Good health ,Dystonic Disorders ,Child, Preschool ,Original Article ,Female ,France ,medicine.symptom ,Chromosomes, Human, Pair 7 ,Adult ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,phenotype ,Nonsense mutation ,Biology ,03 medical and health sciences ,SGCE ,Chorea ,Sarcoglycans ,medicine ,Humans ,Genetic Testing ,essential myoclonus ,030304 developmental biology ,Aged ,Infant ,medicine.disease ,nervous system diseases ,epsilon sarcoglycan gene ,mutation ,030217 neurology & neurosurgery ,Dystonic disorder ,Molecular Chaperones - Abstract
Background: Myoclonus dystonia syndrome (MDS) is an autosomal dominant movement disorder caused by mutations in the epsilon-sarcoglycan gene ( SGCE ) on chromosome 7q21. Methods: We have screened for SGCE mutations in index cases from 76 French patients with myoclonic syndromes, including myoclonus dystonia (M-D), essential myoclonus (E-M), primary myoclonic dystonia, generalised dystonia, dystonia with tremor, and benign hereditary chorea. All coding exons of the SGCE gene were analysed. The DYT1 mutation was also tested. Results: Sixteen index cases had SGCE mutations while one case with primary myoclonic dystonia carried the DYT1 mutation. Thirteen different mutations were found: three nonsense mutations, three missense mutations, three splice site mutations, three deletions, and one insertion. Eleven of the SGCE index cases had M-D and five E-M. No SGCE mutations were detected in patients with other phenotypes. The total number of mutation carriers in the families was 38, six of whom were asymptomatic. Penetrance was complete in paternal transmissions and null in maternal transmissions. MDS patients with SGCE mutation had a significantly earlier onset than the non-carriers. None of the patients had severe psychiatric disorders. Conclusion: This large cohort of index patients shows that SGCE mutations are primarily found in patients with M-D and to a lesser extent E-M, but are present in only 30% of these patients combined (M-D and E-M).
- Published
- 2006
- Full Text
- View/download PDF
16. Impact of silvering stage, age, body size and condition on reproductive potential of the European eel
- Author
-
Sylvie Dufour, Caroline M. F. Durif, Pierre Elie, University of Oslo (UiO), Muséum national d'Histoire naturelle (MNHN), Ecosystèmes estuariens et poissons migrateurs amphihalins (UR EPBX), and Centre national du machinisme agricole, du génie rural, des eaux et forêts (CEMAGREF)
- Subjects
0106 biological sciences ,endocrine system ,Gonad ,animal structures ,media_common.quotation_subject ,Zoology ,Aquatic Science ,Body size ,01 natural sciences ,Vitellogenin ,medicine ,Sexual maturity ,14. Life underwater ,Carp ,Ecology, Evolution, Behavior and Systematics ,media_common ,Ecology ,biology ,010604 marine biology & hydrobiology ,Silvering ,04 agricultural and veterinary sciences ,biology.organism_classification ,Fishery ,medicine.anatomical_structure ,[SDE]Environmental Sciences ,040102 fisheries ,biology.protein ,0401 agriculture, forestry, and fisheries ,Reproduction ,Development of the gonads - Abstract
International audience; Deteriorating reproductive capacities are a possible cause for the decline in eel populations. However, since no sexually maturing adults have ever been found in the open ocean, there is no possible observation of this life-phase in the natural environment. To test whether eels display variations in their reproductive capacity, we investigated the response of the European eel Anguilla anguilla to artificially induced sexual maturation. The objective was to describe the variability in the maturation response of eels in terms of gonad weight and vitellogenin levels and to try and relate this variability to individual characteristics (length, condition, age and silvering stage). We carried out 3 sets of experiments in which sexual maturation was induced in female silver European eels from different locations using weekly carp pituitary extract (CPE) injections. External parameters of eels were measured every week, and several individuals were sacrificed at monthly intervals for blood and organ sampling. Although gonad weight in most treated eels increased by as much as 50% of total body weight, results showed that individual responses were highly variable. Part of this variability could be explained by individual characteristics of eels. Individuals which initially were the most advanced in the silvering process and had a high condition factor showed the best maturation response. Age of eels was correlated with energy stores, and it was shown that eels benefit from delaying their migration and reproduction. Furthermore, highest gonad development was obtained for eels measuring over 700 mm body length.
- Published
- 2006
17. The silvering process of Anguilla anguilla: a new classification from the yellow resident to the silver migrating stage
- Author
-
Sylvie Dufour, Caroline M. F. Durif, Pierre Elie, Ecosystèmes estuariens et poissons migrateurs amphihalins (UR EPBX), Centre national du machinisme agricole, du génie rural, des eaux et forêts (CEMAGREF), and Muséum national d'Histoire naturelle (MNHN)
- Subjects
0106 biological sciences ,endocrine system ,animal structures ,biology ,Anguillicoloides crassus ,Ecology ,010604 marine biology & hydrobiology ,Fish fin ,Zoology ,Silvering ,Aquatic Science ,biology.organism_classification ,Silver eel ,Growth hormone ,010603 evolutionary biology ,01 natural sciences ,Large sample ,Anguillidae ,GONADOTROPIN ,[SDE]Environmental Sciences ,14. Life underwater ,Development of the gonads ,Ecology, Evolution, Behavior and Systematics ,ARGENTAGE - Abstract
International audience; The identification of five stages for female and two stages for male eels Anguilla anguilla using multivariate analysis was carried out on a large sample of individuals collected at six different locations in France. Stages corresponded to a growth phase (stages I and II), a pre-migrant phase (III) and two migrating phases (IV and V). It is likely that an important period of growth triggered silvering through the production of growth hormone (GH) in stage III eels. In migrating eels gonad development, gonadotropin hormone (GTH-II) production and increase of eye surface were similar at all sites. Differences among locations were found in gut regression and pectoral fin length. As variability for these increased with the size of the watershed and values were highest for the most downstream locations, fin length and gut regression may indicate the time since an eel started its migration.
- Published
- 2005
- Full Text
- View/download PDF
18. Tests of two types of bypass for downstream migration of eels at a small hydroelectric power plant
- Author
-
Jacques Rives, F. Travade, Claude Gosset, Caroline M. F. Durif, Pierre Elie, Ecologie Comportementale et Biologie des Populations de Poissons (ECOBIOP), Institut National de la Recherche Agronomique (INRA)-Université de Pau et des Pays de l'Adour (UPPA), EDF (EDF), Ecosystèmes estuariens et poissons migrateurs amphihalins (UR EPBX), and Centre national du machinisme agricole, du génie rural, des eaux et forêts (CEMAGREF)
- Subjects
0106 biological sciences ,Hydrology ,biology ,Ecology ,010604 marine biology & hydrobiology ,Sluice ,[SDV]Life Sciences [q-bio] ,Total efficiency ,biology.organism_classification ,Silver eel ,010603 evolutionary biology ,01 natural sciences ,Range finding ,Current (stream) ,Downstream (manufacturing) ,Anguillidae ,Hydroelectricity ,[SDE]Environmental Sciences ,Environmental Chemistry ,Environmental science ,14. Life underwater ,USINE HYDROELECTRIQUE ,General Environmental Science ,Water Science and Technology - Abstract
Efficiencies of two types of bypass, a surface and a bottom sluice, were tested for the natural downstream migration of silver eels Anguilla anguilla at a small hydroelectric power plant at Halsou, on the River Nive in France. Naturally migrating eels were caught after their passage through either bypass. A total of 637 eels were trapped during the three-year study. Total efficiency for both bypasses, evaluated on the basis of downstream movement of radiotagged eels, ranged from 56% to 64%. Given a bias due to hydrological conditions at the time of the runs, the precise efficiency of each separate bypass was not calculated. However, preferred passage through the bottom bypass for both tagged and untagged eels was confirmed by telemetry, as three to four times as many eels transited through the bottom bypass compared to the surface one. The behaviour of 74 individuals released in the forebay was observed by radiotelemetry. Close to half of the radiotagged eels returned up the headrace after their release, and most eventually migrated downstream over the dam with appropriate environmental conditions. Upon arrival at the power plant, eels displayed foraging behaviour in the forebay with frequent displacement interrupted by long resting periods in zones with low current. The repulsive effect of the trashrack located in front of the turbine intake increased with increasing turbined discharge. The study indicated that a trashrack with a smaller bar-spacing (around 20 mm), associated with an appropriate bypass, could deflect a large proportion of the female eels from the turbines. However, this solution needs to be tested on site to quantify the risk of mortality due to impingement on the trashrack. Copyright © 2005 John Wiley & Sons, Ltd.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.